Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
The oxazolidinone derivative locostatin induces cytokine appeasement.
PMID 19917702 · PMC2799496 · Journal of immunology (Baltimore, Md. : 1950) · 2009 · 7 claims · 7 setups
RKIP is differentially localized (not differentially expressed) on the proteomic map after in vivo T cell recall compared to resting state
-
Full-text index only
T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant.
PMID 8666925 · PMC2192525 · The Journal of experimental medicine · 1996 · 8 claims · 6 setups
Despite heterogeneous TCR usage among clones from different HLA-B14 subjects, the fine specificity for the gp41/584-592 epitope and its variants is strikingly similar.
-
Full-text index only
Candidate vaccine sequences to represent intra- and inter-clade HIV-1 variation.
PMID 19812689 · PMC2753653 · PloS one · 2009 · 7 claims · 5 setups
Natural CTL immunodominance toward variable proteome regions increases epitope mismatch with challenge strains and recapitulates the escape-driven CTL failure seen in natural infection, contributing to HIV vaccine failure
-
Full-text index only
A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes.
PMID 9449708 · PMC2212124 · The Journal of experimental medicine · 1998 · 8 claims · 8 setups
A gene, SART-1, encoding antigenic peptides recognized by HLA-A2601-restricted CTLs was identified from human squamous cell carcinoma cells.
-
Full-text index only
Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.
PMID 19969118 · PMC2821965 · Vaccine · 2010 · 7 claims · 8 setups
rMVA expressing multiple antigens under the mH5 promoter exhibit remarkable genetic stability and maintain potent immunogenicity after serial passage